Penumbra, Inc. (PEN)

US — Healthcare Sector
Peers: INSP  PODD  GKOS  IRTC  LIVN 

Automate Your Wheel Strategy on PEN

With Tiblio's Option Bot, you can configure your own wheel strategy including PEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PEN
  • Rev/Share 32.9639
  • Book/Share 33.3192
  • PB 7.845
  • Debt/Equity 0.1704
  • CurrentRatio 6.7538
  • ROIC 0.0886

 

  • MktCap 10193982329.0
  • FreeCF/Share 4.1618
  • PFCF 63.0726
  • PE 68.7263
  • Debt/Assets 0.1317
  • DivYield 0
  • ROE 0.1241

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade PEN Needham Hold Buy -- $326 Oct. 8, 2025
Initiation PEN Evercore ISI -- Outperform -- $300 Sept. 2, 2025
Initiation PEN BofA Securities -- Buy -- $320 March 14, 2025
Initiation PEN UBS -- Buy -- $305 Jan. 21, 2025
Initiation PEN Oppenheimer -- Outperform -- $275 Dec. 17, 2024
Upgrade PEN Wells Fargo Equal Weight Overweight $190 $275 Dec. 11, 2024
Initiation PEN Stifel -- Buy -- $238 Sept. 18, 2024
Initiation PEN Leerink Partners -- Outperform -- $263 Sept. 3, 2024

News

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors
PEN
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral

ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025.

Read More
image for news Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors
Penumbra (PEN) Upgraded to Buy: Here's Why
PEN
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Penumbra (PEN) Upgraded to Buy: Here's Why
Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript
PEN
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Neutral

Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners …

Read More
image for news Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings
PEN
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Positive

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More
image for news Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings
Should You Add Penumbra Stock to Your Portfolio Right Now?
PEN
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive

PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.

Read More
image for news Should You Add Penumbra Stock to Your Portfolio Right Now?

About Penumbra, Inc. (PEN)

  • IPO Date 2015-09-18
  • Website https://www.penumbrainc.com
  • Industry Medical - Devices
  • CEO Adam Elsesser
  • Employees 4500

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.